Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 1/20 | 0.34 |
| ▸ | SDC2 | P34741 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28758208 | 0.93 | DPP4 (0.41) | DPP4DPP9DPP8TP53SDCBP | |
| SCHEMBL5453642 | 0.92 | DPP4 (0.46) | DPP4DPP9DPP8TP53MAPT | |
| SCHEMBL5447087 | 0.92 | DPP4 (0.43) | DPP4DPP9DPP8TP53MAPT | |
| SCHEMBL27664833 | 0.86 | DPP4 (0.43) | DPP4DPP9DPP8SDCBPSDC2 | |
| SCHEMBL5443611 | 0.83 | DPP4 (0.50) | DPP4DPP9DPP8 | |
| SCHEMBL5449393 | 0.82 | DPP4 (0.46) | DPP4DPP9DPP8 | |
| SCHEMBL5740583 | 0.80 | DPP4 (0.42) | DPP4DPP9DPP8TP53MAPT | |
| SCHEMBL5445046 | 0.80 | DPP4 (0.42) | DPP4DPP9DPP8MAPTTDP1 | |
| SCHEMBL4113112 | 0.80 | DPP4 (0.66) | DPP4DPP9DPP8 | |
| SCHEMBL5456206 | 0.80 | DPP4 (0.51) | DPP4DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | DPP4 1/4885DPP9 5/4885DPP8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.